Biotron Limited (ASX:BIT) insider Stephen Locarnini bought 800,000 shares of the business’s stock in a transaction on Friday, January 10th. The stock was acquired at an average cost of A$0.05 ($0.04) per share, for a total transaction of A$40,000.00 ($28,368.79).
Shares of BIT opened at A$0.06 ($0.04) on Thursday. The business’s 50 day moving average is A$0.06 and its two-hundred day moving average is A$0.07. Biotron Limited has a 52-week low of A$0.05 ($0.04) and a 52-week high of A$0.14 ($0.10). The firm has a market cap of $37.18 million and a price-to-earnings ratio of -20.33.
Biotron Company Profile
Biotron Limited, a biotechnology company, develops and commercializes novel small molecule antiviral therapeutics to treat various viral diseases in Australia. Its lead antiviral drug is BIT225, which is in Phase II clinical trials for the treatment of HIV-1 and hepatitis C virus infections. The company also has a portfolio of preclinical antiviral programs developing drugs targeting a range of viruses, including dengue, ebola, influenza, and zika, as well as Middle East respiratory virus.
Further Reading: Recession
Receive News & Ratings for Biotron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biotron and related companies with MarketBeat.com's FREE daily email newsletter.